Klaria Pharma Holding AB (KLAR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Klaria Pharma Holding AB (KLAR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8168
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Klaria Pharma Holding AB (Klaria Pharma) is a developer of fast acting medicinal products that designes, develops and commercializ therapeutics for migraine and cancer related pain. The company’s patented drug delivery platform is an alginate-based polymer film, facilitates quick and dependable transmucosal absorption of clinically established and marketed substances. It also offers reliable and stable supply forms than tablets and other delivery systems such as nasal sprays and orally dissolvable tablets. Klaria Pharma offers its products to customers globally through distributors. The company works in partnership with local pharmaceutical companies on clinical trials, registration, marketing, manufacturing, and others. Klaria Pharma is headquartered in Uppsala, Sweden.

Klaria Pharma Holding AB (KLAR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Klaria Pharma Partners with Recipharm and Clinical Trial Consultants 10
Licensing Agreements 11
Purdue Pharma Canada Enters into Licensing Agreement with Klaria Pharma 11
Klaria Pharma Enters into Licensing Agreement with Uppsalagruppen Medical 12
Equity Offering 13
Klaria Pharma Raises USD5.8 Million in Public Offering of Shares 13
Acquisition 14
Klaria Pharma Acquires Klaria AB for USD15.2 Million 14
Klaria Pharma Holding AB – Key Competitors 15
Klaria Pharma Holding AB – Key Employees 16
Klaria Pharma Holding AB – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Klaria Pharma Holding AB, Deals By Therapy Area, 2012 to YTD 2018 8
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Klaria Pharma Partners with Recipharm and Clinical Trial Consultants 10
Purdue Pharma Canada Enters into Licensing Agreement with Klaria Pharma 11
Klaria Pharma Enters into Licensing Agreement with Uppsalagruppen Medical 12
Klaria Pharma Raises USD5.8 Million in Public Offering of Shares 13
Klaria Pharma Acquires Klaria AB for USD15.2 Million 14
Klaria Pharma Holding AB, Key Competitors 15
Klaria Pharma Holding AB, Key Employees 16
Klaria Pharma Holding AB, Subsidiaries 17

List of Figures
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Klaria Pharma Holding AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Klaria Pharma Holding AB (KLAR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dana-Farber Cancer Institute Inc:企業のM&A・事業提携・投資動向
    Dana-Farber Cancer Institute Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dana-Farber Cancer Institute Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • Milagen Inc:企業の製品パイプライン分析
    Summary Milagen Inc (Milagen) is a medical device company. It provides diagnostic products. The company generates antibody reagents against the human proteome. It discovers, develops and markets non invasive immunodiagnostic products for monitoring, surveillance and detection of cancers. Milagen off …
  • Ontario Power Generation Inc.:企業の戦略・SWOT・財務分析
    Ontario Power Generation Inc. - Strategy, SWOT and Corporate Finance Report Summary Ontario Power Generation Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Coca-Cola Icecek A.S.:企業の戦略・SWOT・財務情報
    Coca-Cola Icecek A.S. - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola Icecek A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Thar Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Thar Pharmaceuticals Inc (Thar Pharma), a subsidiary of Grunenthal GmbH is a healthcare solution provider that concentrates on transforming intravenous (IV) drugs into oral drugs for existing and new indications. The company’s lead product T121, an oral form of IV only zoledronic acid, is de …
  • Cape plc:企業の戦略・SWOT・財務情報
    Cape plc - Strategy, SWOT and Corporate Finance Report Summary Cape plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • ICW Group:企業の戦略・SWOT・財務分析
    ICW Group - Strategy, SWOT and Corporate Finance Report Summary ICW Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Mercuria Energy Group Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Mercuria Energy Group Ltd (Mercuria Energy) is an independent energy and commodity company that carries out sourcing, supplying and trading of crude oil and refined petroleum products through its subsidiaries. Its portfolio includes petrochemicals, biofuels, environmental products, natural g …
  • FuelCell Energy Inc (FCEL):電力:M&Aディール及び事業提携情報
    Summary FuelCell Energy Inc (FuelCell Energy) is an integrated fuel cell company that designs, manufactures, installs, operates, and services stationary fuel cell power plants for distributed power generation. The company offers proprietary fuel cell products based on carbonate fuel cell technology. …
  • Corporacion Electrica Nacional SA:企業の戦略的SWOT分析
    Corporacion Electrica Nacional SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Aushon BioSystems Inc:医療機器:M&Aディール及び事業提携情報
    Summary Aushon BioSystems Inc (Aushon) is a medical device provider that provides biomarker measurement and analysis products. The company offers biomarker therapeutic areas in microarray printing technology. It provides products such as ciraplex assay, cirascan imaging and cirasoft analysis and cir …
  • GFI Informatique:企業の戦略・SWOT・財務情報
    GFI Informatique - Strategy, SWOT and Corporate Finance Report Summary GFI Informatique - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • New Zealand Post Limited:企業の戦略的SWOT分析
    New Zealand Post Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • TransGenic Inc (2342):企業の財務・戦略的SWOT分析
    TransGenic Inc (2342) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • CK Infrastructure Holdings Ltd (1038):企業の財務・戦略的SWOT分析
    CK Infrastructure Holdings Ltd (1038) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • PNM Resources, Inc.:発電所・企業SWOT分析
    PNM Resources, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Continental Engineering Corporation:企業の戦略・SWOT・財務分析
    Continental Engineering Corporation - Strategy, SWOT and Corporate Finance Report Summary Continental Engineering Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Power Machines:企業の戦略的SWOT分析
    Power Machines - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • CaixaBank SA:企業の戦略・SWOT・財務情報
    CaixaBank SA - Strategy, SWOT and Corporate Finance Report Summary CaixaBank SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Mediolanum farmaceutici SpA-製薬・医療分野:企業M&A・提携分析
    Summary Mediolanum farmaceutici SpA (Mediolanum) is a healthcare solution provider that discovers, develops and markets pharmaceuticals products and prescription drugs. The company offers products in therapeutic areas which include neuropsychiatric, osteoarticular, antibiotic, pneumoallergological, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆